These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37791528)

  • 1. Targeted covalent inhibitors for novel therapeutics.
    Zhang J; Gao W; Wang Y; Chang J; Yu B
    Future Med Chem; 2023 Oct; 15(19):1739-1741. PubMed ID: 37791528
    [No Abstract]   [Full Text] [Related]  

  • 2. Covalent Inhibition in Drug Discovery.
    Ghosh AK; Samanta I; Mondal A; Liu WR
    ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discovery considerations in the development of covalent inhibitors.
    Mah R; Thomas JR; Shafer CM
    Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10 years into the resurgence of covalent drugs.
    De Vita E
    Future Med Chem; 2021 Jan; 13(2):193-210. PubMed ID: 33275063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
    Chowdhury SR; Kennedy S; Zhu K; Mishra R; Chuong P; Nguyen AU; Kathman SG; Statsyuk AV
    Bioorg Med Chem Lett; 2019 Jan; 29(1):36-39. PubMed ID: 30455147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations.
    Li A; Sun H; Du L; Wu X; Cao J; You Q; Li Y
    J Mol Model; 2014 Nov; 20(11):2515. PubMed ID: 25394401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors.
    Bianco G; Goodsell DS; Forli S
    Trends Pharmacol Sci; 2020 Dec; 41(12):1038-1049. PubMed ID: 33153778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent inhibitors design and discovery.
    De Cesco S; Kurian J; Dufresne C; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2017 Sep; 138():96-114. PubMed ID: 28651155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling.
    Bjij I; Ramharack P; Khan S; Cherqaoui D; Soliman MES
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31466292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal.
    Martín-Gago P; Olsen CA
    Angew Chem Int Ed Engl; 2019 Jan; 58(4):957-966. PubMed ID: 30024079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
    Aljoundi A; Bjij I; El Rashedy A; Soliman MES
    Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.
    Guilinger JP; Archna A; Augustin M; Bergmann A; Centrella PA; Clark MA; Cuozzo JW; Däther M; Guié MA; Habeshian S; Kiefersauer R; Krapp S; Lammens A; Lercher L; Liu J; Liu Y; Maskos K; Mrosek M; Pflügler K; Siegert M; Thomson HA; Tian X; Zhang Y; Konz Makino DL; Keefe AD
    Bioorg Med Chem; 2021 Jul; 42():116223. PubMed ID: 34091303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent binders in drug discovery.
    Vasudevan A; Argiriadi MA; Baranczak A; Friedman MM; Gavrilyuk J; Hobson AD; Hulce JJ; Osman S; Wilson NS
    Prog Med Chem; 2019; 58():1-62. PubMed ID: 30879472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.
    Pettinger J; Carter M; Jones K; Cheeseman MD
    J Med Chem; 2019 Dec; 62(24):11383-11398. PubMed ID: 31725295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research progress of the small molecule covalent inhibitors].
    Yang B; Wang WJ; Li LL
    Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent Small Molecules as Enabling Platforms for Drug Discovery.
    Dalton SE; Campos S
    Chembiochem; 2020 Apr; 21(8):1080-1100. PubMed ID: 31833626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
    Kumalo HM; Bhakat S; Soliman ME
    Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.